Jens Eckstein

Jens Eckstein General Information

Description

Dr. Jens Eckstein serves as an Investment Partner at Hevolution Foundation. He serves as President at Samsara Therapeutics. He serves as an Advisor at Refoxy Pharma. He serves as an Advisor at Apollo Health Ventures. Previously, he served as Managing Partner at Apollo Health Ventures. He also serves as a Board Member at Vandria and Haya Therapeutics. Previously, he served as President at SR One. He served as Chairman at Aeovian Pharmaceuticals. He is also a member of the Board of Directors of CoNCERT Pharmaceuticals and Magen Biosciences and served as an Advisor to Sirtris Pharmaceuticals. Before joining TMV, he was Director, Lead Discovery and Research IT at Enanta Pharmaceuticals, where he directed the company's lead discovery and knowledge management programs for novel therapeutics in hepatitis, asthma, psoriasis, and other autoimmune disorders. Before that, he managed research groups in biochemistry, structural biology, and computational chemistry at Mitotix (now GPC-Biotech) where he led the $48 million research collaboration with the BASF Bioresearch Corporation (BBC) on Cdc25 anticancer therapeutics. He is an Alumnus of the Kauffman Fellows Program. He earned his doctorate in biological chemistry from the University of Konstanz and Harvard University. He served as a Board Member at Gladius Pharmaceuticals, Thrasos Innovation & Palleon Pharmaceuticals. He was a Co-Founder of Decibel Therapeutics. He served as a Board Member and Advisor at Cleara. He earned his Ph.D in Biological Chemistry from Harvard University in 1991 and a Diploma in Chemistry from the University of Konstanz in 1987.